Synbio Tech Inc

As of June 30, 2026, Synbio Tech Inc carries a market capitalization of 1.66B, placing it among publicly traded companies globally. Its enterprise value stands at 2.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Synbio Tech Inc's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Synbio Tech Inc has 34.58M shares outstanding.

As of June 30, 2026, Synbio Tech Inc trades at a trailing price-to-earnings ratio of 11.67. The price-to-sales ratio is 1.65, and the price-to-book ratio stands at 1.27.

As of June 30, 2026, Synbio Tech Inc trades at an EV/EBITDA multiple of 11.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.52 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.80B versus a market cap of 1.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Synbio Tech Inc maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 125.38, indicating elevated leverage, while an interest coverage ratio of 8.31 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Synbio Tech Inc posted a return on equity (ROE) of 11.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.75, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.28, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.02 indicates how many times Synbio Tech Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Synbio Tech Inc recorded 9.05M in income tax expense. That works out to an effective tax rate of 5.99, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 151.11M, leaving 142.06M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Synbio Tech Inc's stock has declined approximately 59.92% over the past 52 weeks. The 50-day moving average sits at 46.53, while the 200-day moving average is 58.60.

Over the twelve months ended June 30, 2026, Synbio Tech Inc generated 1.01B in revenue and converted that into 142.06M in net income, yielding earnings per share of 4.11. EBITDA reached 246.80M, while operating income came in at 130.21M.

As of June 30, 2026, Synbio Tech Inc holds 500.73M in cash and equivalents against 1.64B in total debt, resulting in a net debt position of 1.19B. Total book value stands at 1.31B, with working capital of 74.46M providing operational flexibility.

Synbio Tech Inc produced 183.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -476.13M in capital expenditures, free cash flow totaled -292.65M - equivalent to -8.47 per share.

Over the twelve months ended June 30, 2026, Synbio Tech Inc posted a gross margin of 50.02, reflecting its pricing power and cost economics. The operating margin of 12.94 and net profit margin of 14.11 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Synbio Tech Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -17.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.87, meaning Synbio Tech Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Synbio Tech Inc's most recent stock split took place on June 29, 2026.

As of June 30, 2026, Synbio Tech Inc has an Altman Z-Score of 1.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.